Prior, he was in PfizerвЂ™s drug discovery research group in La Jolla as part of the Medicinal Chemistry Department. Prior to joining Zentalis, Kevin was a co-founder of Kalyra Pharmaceuticals and currently serves on the board of directors of Kalyra and as its Chief Scientific/Operations Officer. Kevin is a co-founder and Chief Operating Officer at Zentalis Pharmaceuticals. Interesting Fact: Cam attended the coldest game in NFL history, the Freezer Bowl (-59 degrees wind chill). Cam holds an MBA from the University of San Diego and a BS in Business Administration from Ohio University. Prior to these roles, he held leadership positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma.

He was also the Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Previously, Cam was a board member and Chief Business Officer at Retrosense Therapeutics, which was acquired by Allergan. From April 2016 to May 2022, he was the Chief Business Officer of Immusoft, a private company developing gene modified cell therapies for orphan diseases. He was also a founding Board member of VelosBio until its acquisition by Merck. In addition to Zentalis, Cam currently serves on the Board of Directors of Ocuphire, Helios, SelectION and Ray Therapeutics. He has 30 years of experience in the life sciences, with a focus on corporate development, marketing and company formation, and financing. She holds a BA degree in Bioethics from Duke University and a MD degree from Mayo Clinic Medical School.Д¬am is a cofounder and President at Zentalis Pharmaceuticals and has served as a member of the Board of Directors since the CompanyвЂ™s founding. This work led to KimвЂ™s inclusion in TIME MagazineвЂ™s 100 Most Influential People in the World for 2013, recognizing her accomplishments contributing to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. As one of the nationвЂ™s leading breast cancer researchers, she played a role in developing therapies that represent revolutionary non-chemotherapy-based approaches for treating cancer. While at Duke, she served as the principal or co-principal investigator for over 50 cancer clinical trials, co-founded the radiotherapeutics company-Cereius, and co-directed the WomanвЂ™s Cancer Program and Precision Medicine Initiative. For 18 years, Kim was a faculty member at the Duke University Cancer Institute. During her time at Lilly, she was named as one of вЂњTwenty extraordinary women in biopharma R&D who worked their way to the topвЂќ by Endpoints News. Prior to joining Tempus, Kim was VP of Early Phase Oncology and Immunology-oncology at Eli Lilly and Company, where she worked on early stage cancer therapeutics. In this role, she oversaw precision medicine initiatives to improve cancer care and guide therapeutic drug development and discovery. Prior to joining Zentalis, she served as Chief Medical Officer and Senior Vice President, Oncology Clinical Development, at Tempus Labs. Kimberly is the Chief Executive Officer at Zentalis Pharmaceuticals. The launch of Zentera is a key milestone in our global clinical development strategy and is the first step toward advancing our potentially best-in-class therapeutic candidates to markets worldwide. and ZN-c5), in addition to potential future candidates, in China. In May 2020, we established Zentera Therapeutics, our Chinese joint venture, to develop and commercialize three Zentalis-discovered oncology candidates (ZN-c3, ZN-d5. We believe our deep pipeline of oncology therapeutic candidates has the potential to significantly improve the lives of patients with various types of cancer. This approach has allowed us to advance a diverse pipeline in a capital efficient manner, clearing four INDs with the FDA within the first five years. Leveraging our extensive industry experience and know-how, we developed our Integrated Discovery Engine-our working model for generating potentially differentiated product candidates that are designed to target distinct cancer pathways. Our experienced team is comprised of industry leaders with proven track records in the discovery, clinical development, and commercialization of innovative cancer therapies. We are dedicated to the discovery and development of small molecule therapeutics targeting fundamental biological pathways of cancer. Our Company Developing small molecule therapeutics with differentiated product profiles for a broad range of cancers

Ceo of ecrisper